Nucana Plc ADR (NCNA) Stock Price, Quote & News

Company Profile

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company is developing medicines to overcome the limitations of nucleoside analogs and generate anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil that is in Phase...

Industry: Biotechnology

Sector: Healthcare

Phone: 44 13 1357 1111

Website: www.nucana.com

Address:

3 Lochside Way, Edinburgh, United Kingdom

lffld Mar. 20 at 8:54 PM

$NCNA that's clear 1 ADR =5000 ordinary shares.

1 · Reply

Panicmode Mar. 20 at 8:18 PM

$NCNA the pre RS kids that held and posted nonstop they were buying the dip have even vanished.. 🤣🤣🥰🤣

2 · Reply

cycloon Mar. 20 at 8:17 PM

$NCNA https://ir.nucana.com/sec-filings/sec-filing/3/0001193125-26-117653

0 · Reply

J_machete Mar. 20 at 7:48 PM

$NCNA I hope this gets to 5 soon so I can get rid of it

0 · Reply

GreenEnergy1 Mar. 20 at 7:21 PM

$NCNA Financial results without a public statement and only ”speculation on trials” is HORRIBLE news. Pharma companies often avoid public statements to ensure they don't violate laws suggesting positive results when things are falling apart. Pharma companies are the #1 industry to go bankrupt and Nucana ”expects” to have cash flow through 2029, but that doesn't mean they have it currently and they're still losing tens of millions of dollars each year!

0 · Reply

GreenEnergy1 Mar. 20 at 7:13 PM

$NCNA AND ANOTHER 52 WEEK LOW!!!! 4 Times this week!

0 · Reply

Jeff1367 Mar. 20 at 4:07 PM

$NCNA Can anyone explain these recent fillings to me? It looks like major dilution is coming if these insiders exercise their options. Am I reading that correctly?

2 · Reply

cycloon Mar. 20 at 3:37 PM

$NCNA If the boss buys, things go well.

1 · Reply

cycloon Mar. 20 at 3:12 PM

$NCNA NUC-7738 Demonstrates Clinical Activity and Favorable Safety in Patients with PD-1 Inhibitor-Resistant Melanoma Final Data from Phase 2 Expansion Study of NUC-7738 Expected in 2026 Advancing Additional Indications and Combination Strategies Cash Runway Expected to Extend into 2029

0 · Reply

Benja69 Mar. 20 at 1:38 PM

$NCNA

0 · Reply

NuCana Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Business Update

Jan 6, 2026, 8:00 AM EST - 2 months ago

NuCana Appoints Theresa Bruce as Chief Operating Officer

Dec 10, 2025, 8:00 AM EST - 3 months ago

NuCana Presents Latest Data Demonstrating Clinical Activity and Favorable Safety for NUC-7738 in Patients with PD-1-Resistant Melanoma

Nov 13, 2025, 4:01 PM EST - 4 months ago

NuCana Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 5, 2025, 8:00 AM EST - 4 months ago

NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in China

Sep 5, 2025, 8:00 AM EDT - 7 months ago

NuCana Compliant with All Nasdaq Continued Listing Criteria

Sep 3, 2025, 8:00 AM EDT - 7 months ago

NuCana to Present Data on NUC-7738's Synergy with PD-1 Inhibitors at the ESMO Congress 2025

Aug 20, 2025, 4:05 PM EDT - 7 months ago

NuCana Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 1, 2025, 4:05 PM EDT - 8 months ago

NuCana Announces ADS Ratio Change

Jul 21, 2025, 8:05 AM EDT - 8 months ago

NuCana Cancels All Outstanding Series A Warrants Following Strategic ATM Execution

Jul 11, 2025, 10:30 AM EDT - 9 months ago

NuCana Announces Plan to Implement ADS Ratio Change

Jun 2, 2025, 4:01 PM EDT - 10 months ago

NuCana Reports First Quarter 2025 Financial Results and Provides Business Update

Mar 20, 2025, 4:01 PM EDT - 1 year ago

NuCana Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update

Feb 10, 2025, 7:00 AM EST - 1 year ago

Aurion Biotech Appoints Donald Munoz as Chief Financial Officer

Nov 25, 2024, 7:00 AM EST - 1 year ago

NuCana Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 11, 2024, 7:00 AM EST - 1 year ago

NuCana Announces Encouraging Initial Data from Phase 1b/2 Modular Study of NUC-3373 in Combination with Pembrolizumab or Docetaxel

Oct 4, 2024, 12:03 PM EDT - 1 year ago

Baillie Gifford's Strategic Acquisition of NuCana PLC Shares

Sep 25, 2024, 4:01 PM EDT - 1 year ago

NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in the United States

$NuCana Presents Encouraging Data on NUC-7738 in Combination with Pembrolizumab in PD-1 Inhibitor Refractory and Resistant Melanoma Patients at the ESMO Congress 2024$

Sep 14, 2024, 3:01 AM EDT - 1 year ago

NuCana Presents Encouraging Data on NUC-7738 in Combination with Pembrolizumab in PD-1 Inhibitor Refractory and Resistant Melanoma Patients at the ESMO Congress 2024

Aug 29, 2024, 4:01 PM EDT - 1 year ago

NuCana Announces Update for Phase 2 Randomized Colorectal Cancer Study

Aug 15, 2024, 4:01 PM EDT - 1 year ago

NuCana Reports Second Quarter 2024 Financial Results and Provides Business Update

May 30, 2024, 8:36 AM EDT - 1 year ago

NuCana to Present at the Jefferies Global Healthcare Conference

May 21, 2024, 8:00 AM EDT - 1 year ago

NuCana to Present at TD Cowen's 5th Annual Oncology Innovation Summit

May 16, 2024, 4:01 PM EDT - 2 years ago

NuCana Reports First Quarter 2024 Financial Results and Provides Business Update

May 1, 2024, 4:01 PM EDT - 2 years ago

NuCana Regains Compliance with Nasdaq Minimum Bid Price Requirement

Apr 9, 2024, 4:30 PM EDT - 2 years ago

NuCana Presents Data at the AACR 2024 Annual Meeting Highlighting the Ability of NUC-7738 to Profoundly Alter Tumor Biology in a Paired Biopsy Clinical Study

Mar 20, 2024, 4:01 PM EDT - 2 years ago

NuCana Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Business Update

Feb 27, 2024, 8:00 AM EST - 2 years ago

NuCana to Present at TD Cowen's 44th Annual Health Care Conference

Nov 16, 2023, 4:01 PM EST - 2 years ago

NuCana Reports Third Quarter 2023 Financial Results and Provides Business Update

Nov 10, 2023, 4:01 PM EST - 2 years ago

NuCana Announces Listing Transfer to Nasdaq Capital Market

Nov 8, 2023, 4:01 PM EST - 2 years ago

NuCana to Present at the Jefferies London Healthcare Conference

Nov 1, 2023, 4:01 PM EDT - 2 years ago

NuCana to Participate in the Truist Securities 2023 BioPharma Symposium

Oct 16, 2023, 7:00 AM EDT - 2 years ago

NuCana Presents Promising Data on NUC-7738 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023

Oct 13, 2023, 12:30 PM EDT - 2 years ago

NuCana Presents Encouraging Data on NUC-3373 in Colorectal Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023

Sep 18, 2023, 8:00 AM EDT - 2 years ago

NuCana Announces Presentations at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023

Aug 16, 2023, 4:01 PM EDT - 2 years ago

NuCana Reports Second Quarter 2023 Financial Results and Provides Business Update

Jun 1, 2023, 8:00 AM EDT - 3 years ago

NuCana to Present at the Jefferies Healthcare Conference

May 17, 2023, 4:01 PM EDT - 3 years ago

NuCana Reports First Quarter 2023 Financial Results and Provides Business Update

May 12, 2023, 4:01 PM EDT - 3 years ago

NuCana Announces Receipt of Nasdaq Notice

Apr 14, 2023, 8:00 AM EDT - 3 years ago

NuCana Presents Data at the AACR 2023 Annual Meeting Highlighting Novel NUC-7738 Mechanisms of Action

Apr 4, 2023, 4:01 PM EDT - 3 years ago

NuCana Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Business Update

Mar 24, 2023, 4:30 PM EDT - 3 years ago

Technical Board of Appeal of the European Patent Office Issues Oral Ruling that NuCana's ‘190 Patent is Not Valid

Feb 28, 2023, 8:00 AM EST - 3 years ago

NuCana to Participate in Two Upcoming Investor Conferences

Jan 6, 2023, 4:01 PM EST - 3 years ago

NuCana Announces Receipt of NASDAQ Notice

Nov 16, 2022, 4:01 PM EST - 3 years ago

NuCana Reports Third Quarter 2022 Financial Results and Provides Business Update

Oct 26, 2022, 7:00 AM EDT - 3 years ago

NuCana Presents Positive Data on NUC-3373 at the 34th EORTC-NCI-AACR Annual Meeting 2022

Sep 12, 2022, 10:45 AM EDT - 3 years ago

NuCana Presents Promising Data on NUC-7738 at the European Society of Medical Oncology (ESMO) Annual Meeting 2022

Sep 6, 2022, 8:00 AM EDT - 3 years ago

NuCana Announces Presentations at the European Society for Medical Oncology (ESMO) Congress 2022

Aug 31, 2022, 8:00 AM EDT - 3 years ago

NuCana to Participate in Citi's 17th Annual BioPharma Conference

Aug 17, 2022, 4:01 PM EDT - 3 years ago

NuCana Reports Second Quarter 2022 Financial Results and Provides Business Update

lffld Mar. 20 at 8:54 PM

$NCNA that's clear 1 ADR =5000 ordinary shares.

1 · Reply

Panicmode Mar. 20 at 8:18 PM

$NCNA the pre RS kids that held and posted nonstop they were buying the dip have even vanished.. 🤣🤣🥰🤣

2 · Reply

cycloon Mar. 20 at 8:17 PM

$NCNA https://ir.nucana.com/sec-filings/sec-filing/3/0001193125-26-117653

0 · Reply

J_machete Mar. 20 at 7:48 PM

$NCNA I hope this gets to 5 soon so I can get rid of it

0 · Reply

GreenEnergy1 Mar. 20 at 7:21 PM

0 · Reply

GreenEnergy1 Mar. 20 at 7:13 PM

$NCNA AND ANOTHER 52 WEEK LOW!!!! 4 Times this week!

0 · Reply

Jeff1367 Mar. 20 at 4:07 PM

$NCNA Can anyone explain these recent fillings to me? It looks like major dilution is coming if these insiders exercise their options. Am I reading that correctly?

2 · Reply

cycloon Mar. 20 at 3:37 PM

$NCNA If the boss buys, things go well.

1 · Reply

cycloon Mar. 20 at 3:12 PM

0 · Reply

Benja69 Mar. 20 at 1:38 PM

$NCNA

0 · Reply

piotrek123082 Mar. 20 at 12:13 PM

$NCNA but im surprised that the price of stock is this low with really no bad news

1 · Reply

piotrek123082 Mar. 20 at 12:10 PM

$NCNA you sound surprised of the earnings, why? It was known since the start of time that there will be no profits

0 · Reply

FickleFin Mar. 20 at 12:00 PM

$NCNA its game over. Fuck this company.

0 · Reply

DARKP00L Mar. 20 at 11:56 AM

$NCNA 07:52 on Mar. 20 2026 NuCana shares are trading lower. The company reported Q4 financial results. #tradeideas

0 · Reply

Hurtadogoalkeeper Mar. 19 at 8:30 PM

$NCNA

0 · Reply

cycloon Mar. 19 at 8:30 PM

$NCNA https://ir.nucana.com/sec-filings/sec-filing/20-f/0001193125-26-116030

0 · Reply

cycloon Mar. 19 at 8:07 PM

$NCNA https://ir.nucana.com/node/10261/pdf

0 · Reply

GreenEnergy1 Mar. 19 at 2:40 PM

$NCNA Another 52 week low again today!

0 · Reply

lffld Mar. 19 at 1:39 PM

$NCNA did it says 12% for 265000 shares?

2 · Reply

piotrek123082 Mar. 19 at 1:32 PM

$NCNA no wonder why this chat is dead ( except Green Energy still talking to himself here) so is the volume with the stock dead RIP

1 · Reply

piotrek123082 Mar. 19 at 1:29 PM

$NCNA what a piece of shit stock $1.70 thats pre split which would be $0.0085 todays price

0 · Reply

GreenEnergy1 Mar. 19 at 12:17 PM

$NCNA Buying this drop is idiotic! Nucana isn’t dipping, it’s got stage 4 cancer and dying! How many 52 week lows does anyone need to see? How low does the volume need to get? This is trading below $.01 at it’s ”real” price (pre-reverse split). DON’T BUY NCNA

1 · Reply

Market Cap	53,000.00
Revenue (ttm)	0.00
Net Income (ttm)	-24.28M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	46,200
Avg Vol	61,680
Day's Range	N/A - N/A
Shares Out	30,000.00
Stochastic %K	4%
Beta	1.69
Analysts	Strong Buy
Price Target	$25.00